Apathy in patients with Alzheimer's disease is a cost-driving factor
Abstract Background Apathy is the most frequent neuropsychiatric symptom in patients with dementia of the Alzheimer's type (DAT). We analyzed the influence of apathy on the resource use of DAT patients and their caregivers. Methods Included were baseline data of 107 DAT patients from a randomiz...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2023
|
| In: |
Alzheimer's and dementia
Year: 2023, Jahrgang: 19, Heft: 7, Pages: 2853-2864 |
| ISSN: | 1552-5279 |
| DOI: | 10.1002/alz.12915 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/alz.12915 Verlag, kostenfrei, Volltext: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12915 |
| Verfasserangaben: | Christopher Kruse, Franziska Maier, Annika Spottke, Jan-Philipp Bach, Claudia Bartels, Katharina Buerger, Andreas Fellgiebel, Klaus Fliessbach, Lutz Frölich, Lucrezia Hausner, Martin Hellmich, Stefan Klöppel, Arne Klostermann, Johannes Kornhuber, Christoph Laske, Oliver Peters, Josef Priller, Tanja Richter-Schmidinger, Anja Schneider, Kija Shah-Hosseini, Stefan Teipel, Christine AF von Arnim, Jens Wiltfang, Hendrik van der Wurp, Richard Dodel, Frank Jessen |
| Zusammenfassung: | Abstract Background Apathy is the most frequent neuropsychiatric symptom in patients with dementia of the Alzheimer's type (DAT). We analyzed the influence of apathy on the resource use of DAT patients and their caregivers. Methods Included were baseline data of 107 DAT patients from a randomized clinical trial on apathy treatment. The Resource Utilization in Dementia (RUD) instrument assessed costs over a 1-month period prior to baseline. Cost predictors were determined via a least absolute shrinkage and selection operator (LASSO). Results On average, total monthly costs were EUR 3070, of which EUR 2711 accounted for caregivers' and EUR 359 for patients' costs. An increase of one point in the Apathy Evaluation Scale resulted in a 4.1% increase in total costs. Discussion Apathy is a significant cost driving factor for total costs in mild to moderate DAT. Effective treatment of apathy might be associated with reduced overall costs in DAT. |
|---|---|
| Beschreibung: | Erstveröffentlichung: 2. Januar 2023, korrigierte Fassung: 11. Februar 2023 Gesehen am 30.01.2024 |
| Beschreibung: | Online Resource |
| ISSN: | 1552-5279 |
| DOI: | 10.1002/alz.12915 |